S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83

Cyclacel Pharmaceuticals Stock Forecast, Price & News

+0.23 (+6.89%)
(As of 12/7/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
122,515 shs
Average Volume
273,627 shs
Market Capitalization
$35.61 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive CYCC News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyclacel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Cyclacel Pharmaceuticals logo

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company builds a biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.


Vow ASA: Vow bags USD 5.2 million cruise retrofit contract
December 7, 2021 |  finance.yahoo.com
Benzinga Insights
June 6, 2021 |  benzinga.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$150 thousand
Book Value
$4.15 per share


Net Income
$-8.44 million
Pretax Margin




Free Float
Market Cap
$35.61 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.18 out of 5 stars

Medical Sector

419th out of 1,394 stocks

Pharmaceutical Preparations Industry

191st out of 673 stocks

Analyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Frequently Asked Questions

Is Cyclacel Pharmaceuticals a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cyclacel Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Cyclacel Pharmaceuticals stock.
View analyst ratings for Cyclacel Pharmaceuticals
or view top-rated stocks.

How has Cyclacel Pharmaceuticals' stock price been impacted by Coronavirus?

Cyclacel Pharmaceuticals' stock was trading at $0.5399 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CYCC shares have increased by 561.2% and is now trading at $3.57.
View which stocks have been most impacted by COVID-19

When is Cyclacel Pharmaceuticals' next earnings date?

Cyclacel Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Cyclacel Pharmaceuticals

How were Cyclacel Pharmaceuticals' earnings last quarter?

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) issued its earnings results on Wednesday, November, 10th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.70) by $0.16. During the same period last year, the business posted ($0.47) EPS.
View Cyclacel Pharmaceuticals' earnings history

When did Cyclacel Pharmaceuticals' stock split? How did Cyclacel Pharmaceuticals' stock split work?

Cyclacel Pharmaceuticals's stock reverse split before market open on Wednesday, April 15th 2020. The 1-20 reverse split was announced on Tuesday, April 14th 2020. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 14th 2020. An investor that had 100 shares of Cyclacel Pharmaceuticals stock prior to the reverse split would have 5 shares after the split.

What price target have analysts set for CYCC?

2 equities research analysts have issued twelve-month price objectives for Cyclacel Pharmaceuticals' stock. Their forecasts range from $17.00 to $17.00. On average, they expect Cyclacel Pharmaceuticals' share price to reach $17.00 in the next year. This suggests a possible upside of 376.2% from the stock's current price.
View analysts' price targets for Cyclacel Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Cyclacel Pharmaceuticals' key executives?

Cyclacel Pharmaceuticals' management team includes the following people:
  • Spiro Rombotis, President, Chief Executive Officer & Director
  • Paul McBarron, Secretary, Chief Operating & Financial Officer
  • Mark Kirschbaum, Chief Medical Officer & Senior Vice President
  • Amartya Basu, Senior Director-Business Development

What is Spiro Rombotis' approval rating as Cyclacel Pharmaceuticals' CEO?

1 employees have rated Cyclacel Pharmaceuticals CEO Spiro Rombotis on Glassdoor.com. Spiro Rombotis has an approval rating of 100% among Cyclacel Pharmaceuticals' employees. This puts Spiro Rombotis in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Cyclacel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cyclacel Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Vaxart (VXRT), NVIDIA (NVDA), Novavax (NVAX), Gilead Sciences (GILD), Heat Biologics (HTBX), McEwen Mining (MUX) and Tesla (TSLA).

What is Cyclacel Pharmaceuticals' stock symbol?

Cyclacel Pharmaceuticals trades on the NASDAQ under the ticker symbol "CYCC."

Who are Cyclacel Pharmaceuticals' major shareholders?

Cyclacel Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Tri Locum Partners LP (5.66%), Affinity Asset Advisors LLC (4.33%), Two Sigma Advisers LP (1.32%), Morgan Stanley (1.22%), Pura Vida Investments LLC (1.14%) and Geode Capital Management LLC (0.64%). Company insiders that own Cyclacel Pharmaceuticals stock include Sam L Barker and Spiro George Rombotis.
View institutional ownership trends for Cyclacel Pharmaceuticals

Which major investors are selling Cyclacel Pharmaceuticals stock?

CYCC stock was sold by a variety of institutional investors in the last quarter, including Pura Vida Investments LLC, Raymond James Financial Services Advisors Inc., Two Sigma Investments LP, and Morgan Stanley.
View insider buying and selling activity for Cyclacel Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Cyclacel Pharmaceuticals stock?

CYCC stock was purchased by a variety of institutional investors in the last quarter, including Tri Locum Partners LP, Two Sigma Advisers LP, Citadel Advisors LLC, Affinity Asset Advisors LLC, Dimensional Fund Advisors LP, Geode Capital Management LLC, and NEXT Financial Group Inc.
View insider buying and selling activity for Cyclacel Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Cyclacel Pharmaceuticals?

Shares of CYCC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cyclacel Pharmaceuticals' stock price today?

One share of CYCC stock can currently be purchased for approximately $3.57.

How much money does Cyclacel Pharmaceuticals make?

Cyclacel Pharmaceuticals has a market capitalization of $35.61 million and generates $150 thousand in revenue each year. The biotechnology company earns $-8.44 million in net income (profit) each year or ($2.94) on an earnings per share basis.

How many employees does Cyclacel Pharmaceuticals have?

Cyclacel Pharmaceuticals employs 2,018 workers across the globe.

What is Cyclacel Pharmaceuticals' official website?

The official website for Cyclacel Pharmaceuticals is www.cyclacel.com.

Where are Cyclacel Pharmaceuticals' headquarters?

Cyclacel Pharmaceuticals is headquartered at 200 CONNELL DRIVE SUITE 1500, BERKELEY HEIGHTS NJ, 07922.

How can I contact Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals' mailing address is 200 CONNELL DRIVE SUITE 1500, BERKELEY HEIGHTS NJ, 07922. The biotechnology company can be reached via phone at (908) 517-7330, via email at [email protected], or via fax at 866-271-3466.

This page was last updated on 12/8/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.